A fail­ure at Eli Lil­ly, the come­back drug teplizum­ab shows off more up­beat di­a­betes da­ta in the run-up to an FDA fil­ing

Proven­tion Bio has some more pos­i­tive da­ta to add to its loom­ing BLA for a new treat­ment de­signed to de­lay the on­set of di­a­betes among pa­tients.

Their new tri­al da­ta for teplizum­ab boost­ed the av­er­age amount of time it takes for a pa­tient to be di­ag­nosed with type 1 di­a­betes to 5 years, adding a year to their ear­li­er num­ber com­pared to a steady 2 years for the place­bo arm.

Re­searchers added that they are track­ing clear ev­i­dence that the drug can sta­bi­lize and then re­verse de­te­ri­o­rat­ing C-pep­tide lev­els, “sug­gest­ing a de­lay in the de­struc­tion of be­ta cells and restora­tion of in­sulin pro­duc­tion by dys­func­tion­al be­ta cells. Im­por­tant­ly, even in those who ad­vanced to clin­i­cal-stage T1D, treat­ment with teplizum­ab re­sult­ed in a slow­er de­cline in C-pep­tide lev­els com­pared to place­bo.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER